Literature DB >> 1321488

Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans.

C J Bang1, B Riedel, I Talstad, A Berstad.   

Abstract

The haemorrhagic effect of unfractionated heparin and of the low molecular weight heparin, enoxaparin, on gastric mucosal bleeding induced by acetylsalicylic acid (ASA) and on skin bleeding induced by the Simplate technique was investigated in healthy human volunteers. Endoscopic estimation of gastric bleeding by visual analogue scores was more sensitive than biochemical quantitation of blood in the gastric washing by a modified HaemoQuant method. Contrary to what was expected, the ASA-induced gastric mucosal bleeding was not increased by heparin pretreatment, whereas heparin in combination with ASA, but not ASA alone, significantly increased the skin bleeding time. In the interaction with ASA, enoxaparin and unfractionated heparin appeared to act similarly.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1321488     DOI: 10.3109/00365529209000110

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  4 in total

1.  Aspirin related gastrointestinal bleeders have an exaggerated bleeding time response due to aspirin use.

Authors:  A I Lanas; M T Arroyo; F Esteva; R Cornudella; B I Hirschowitz; R Sáinz
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

2.  Interaction between the LMWH reviparin and aspirin in healthy volunteers.

Authors:  U Klinkhardt; H K Breddin; H U Esslinger; S Haas; A Kalatzis; S Harder
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

Review 3.  Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  J R Brouwers; P A de Smet
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

Review 4.  Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease.

Authors:  S Noble; D H Peters; K L Goa
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.